Recommended Initial Treatment for Treatment-Naïve HCV Without Decompensated Cirrhosis
For treatment-naïve adults with hepatitis C virus infection, no decompensated cirrhosis, and creatinine clearance >30 mL/min, use either glecaprevir/pibrentasvir (300/120 mg) for 8 weeks or sofosbuvir/velpatasvir (400/100 mg) for 12 weeks 1, 2.
Treatment Regimen Selection
Both pangenotypic regimens are first-line options with equivalent efficacy (>95% SVR rates), but differ in treatment duration:
Option 1: Glecaprevir/Pibrentasvir (Preferred for Shorter Duration)
- Dosing: 300 mg glecaprevir/120 mg pibrentasvir once daily with food
- Duration: 8 weeks for patients without cirrhosis 1, 2
- Duration: 8-12 weeks for compensated cirrhosis (Child-Pugh A) - though 8 weeks is increasingly supported, 12 weeks provides additional safety margin in those with portal hypertension signs 2
Option 2: Sofosbuvir/Velpatasvir
- Dosing: 400 mg sofosbuvir/100 mg velpatasvir once daily
- Duration: 12 weeks regardless of cirrhosis status 1, 2
Key Clinical Considerations
Cirrhosis Assessment (Required Before Treatment): Calculate FIB-4 score first. Cirrhosis is presumed if 1:
- FIB-4 >3.25, OR
- Transient elastography >12.5 kPa, OR
- Platelet count <150,000/mm³ with clinical signs, OR
- Imaging showing nodularity/splenomegaly
Drug-Drug Interaction Assessment:
- Critical: Glecaprevir/pibrentasvir (protease inhibitor-containing) has more frequent drug interactions than sofosbuvir/velpatasvir 3
- Check all medications including over-the-counter and herbal supplements before prescribing
- Use AASLD/IDSA guidance or University of Liverpool interaction checker 1
On-Treatment Monitoring Requirements
Minimal laboratory monitoring is needed 1:
- Diabetes patients: Monitor for symptomatic hypoglycemia (DAAs improve glucose control)
- Warfarin patients: Monitor INR for subtherapeutic anticoagulation
- All others: No routine laboratory monitoring required
No genotype testing is required before initiating these pangenotypic regimens, though it remains useful for optimization if readily available 2.
Common Pitfalls to Avoid
- Do not use glecaprevir/pibrentasvir if eGFR <30 mL/min - this is a contraindication due to protease inhibitor component 1
- Ensure glecaprevir/pibrentasvir is taken with food - absorption is significantly reduced on empty stomach 1
- Do not assume 8 weeks is sufficient for all cirrhotic patients - those with signs of portal hypertension (liver stiffness >20 kPa AND platelets <150,000/mm³) may benefit from 12 weeks of glecaprevir/pibrentasvir 2
- Screen for hepatocellular carcinoma before treatment in cirrhotic patients - treatment does not eliminate HCC risk 4
Special Population Note
Genotype 3 with compensated cirrhosis represents a more challenging scenario where treatment-naïve patients may benefit from ribavirin addition or the triple therapy sofosbuvir/velpatasvir/voxilaprevir, though glecaprevir/pibrentasvir for 12 weeks remains an acceptable option 2.